INVESTINGBest Stocks of the Decade: Acadia’s Drug Development SuccessBy Scott Van VoorhisJan 5, 2020 10:36 PM EST
STOCKSAcadia Pharma Jumps on Positive Data From Depression Treatment CandidateBy Tony OwusuSep 23, 2019 11:17 AM EDT
JIM CRAMERFord, Domo, Acadia Pharmaceuticals: 'Mad Money' Lightning RoundBy Scott RuttSep 12, 2019 8:51 PM EDT
INVESTINGAcadia Pharmaceuticals Surges on Positive Trial Results for Psychosis TreatmentBy M. Corey GoldmanSep 9, 2019 11:31 AM EDT
STOCKSAcadia Falls Sharply in After-Hours Trading After Schizophrenia Drug Fails StudyBy Tom BemisJul 22, 2019 5:56 PM EDT
JIM CRAMERBerkshire Hathaway, Oneok, FNB Corp.: 'Mad Money' Lightning RoundBy Scott RuttNov 28, 2018 8:45 PM EST
JIM CRAMERDropbox, XPO Logistics, Ford Motor: 'Mad Money' Lightning RoundBy Scott RuttOct 24, 2018 11:04 PM EDT
JIM CRAMERDon't Forget the Consumer: Cramer's 'Mad Money' RecapBy Scott RuttOct 24, 2018 11:04 PM EDT
JIM CRAMERLennar, LG Homes, GrubHub, Sprint: 'Mad Money' Lightning RoundBy Scott RuttApr 20, 2018 6:55 AM EDT
JIM CRAMERWhat's Holding Up This Market?: Cramer's 'Mad Money' RecapBy Scott RuttDec 12, 2017 6:16 AM EST
MERGERS AND ACQUISITIONS7 Potential New Targets for Activist Investor That Made a Killing on Whole FoodsBy Ronald OrolJul 21, 2017 1:15 PM EDT
INVESTINGJana Partners Liquidates Whole Foods Stake After Engineering Industry-Transforming Sale To AmazonBy Ronald OrolJul 19, 2017 4:46 PM EDT
INVESTINGWhy I Hate the FAANGs (but Like Banks and Biotech) for 2017's Second HalfBy Bret JensenJul 10, 2017 4:02 PM EDT
MERGERS AND ACQUISITIONSThe Activist Who Pushed Whole Foods Into the Arms of Amazon Could Target These Companies NextBy Ronald OrolJun 19, 2017 9:47 PM EDT
INVESTINGGood, the Bad and the Ugly; What Troubles Me: Doug Kass' ViewsBy Doug KassMay 1, 2017 1:00 AM EDT
INVESTINGTakeaways and Observations; What's Driving My Approach: Doug Kass' ViewsBy Doug KassMay 1, 2017 1:00 AM EDT
STOCKSSage Therapeutics leads biotech movers on erroneous takeout rumorBy Alicia McElhaneyFeb 17, 2017 9:42 AM EST
STOCKSBiotech Stock Mailbag: Bulls love a distracted Trump, Protalix, Acadia, SareptaBy Adam FeuersteinFeb 17, 2017 7:44 AM EST
STOCKSAcadia Pops on Takeout Rumors, But Don't Buy on M&A Just YetBy Alicia McElhaneyFeb 3, 2017 1:29 PM EST
